Integrative Physiology |
From the Institut für Pharmakologie und Toxikologie der TU München (M.S., V.V., C.H., A.P., T.K., P.R., F.H.), München, Germany; Institut für Physiologie der Universität Rostock (R.S.), Rostock, Germany; and Abteilung Pharmakologie für Pharmazeuten, Universitätskrankenhaus Eppendorf (M.K.), Hamburg, Germany.
Correspondence to Franz Hofmann, Institut für Pharmakologie und Toxikologie der TU München, Biedersteiner Str 29, 80802 München, Germany. E-mail pharma{at}ipt.med.tu-muenchen.de \ © 2000 American Heart Association, Inc.
| Abstract |
|---|
|
|
|---|
Key Words: cGMP-dependent protein kinase I arteries K+ channels
| Introduction |
|---|
|
|
|---|
The important effector of cGMP, cGKI, is highly expressed in smooth muscle. Deletion of the gene for cGKI can led to multiple phenotypes, including high blood pressure in young mice.17 Interestingly, and in contrast to previous suggestions,13 adenosine A2 receptor- and cAMP-dependent relaxation of aortic rings was not affected by the lack of cGKI.17 Older cGKI-deficient (cGKI/) mice, many of which have multiple infections, have normal or only slightly elevated blood pressure,17 suggesting that cGKI is not absolutely required to lower vascular tone and can be bypassed. A potential alternative pathway could be an increased production of endothelium-derived hyperpolarizing factors (EDHF).18 Activation of large and small KCa channels, calcium-activated chloride channels, or voltage-dependent K+ channels by EDHF or NO would hyperpolarize the membrane, close calcium channels, and reduce cytosolic calcium concentrations ([Ca2+]i).14 18
Thus far, the in vitro analysis of hypertensive knockout mice has been performed on isolated aortic segments. In our studies, we noticed that aortic segments can be relaxed by high concentrations of NO in the absence of cGKI. To investigate whether this is also valid for other vessels, we used a small artery (arteria tibialis) that may behave similar to resistance vessels and develop a spontaneous myogenic tone in wild-type (wt) and cGKI/ mice. In this study, we show that high concentrations of NO relax vascular smooth muscle independent of the activation of Ca2+-activated K+ (BKCa) channels by cGMP-dependent cross-activation of cAMP kinase (cAK). This pathway may be important in situations where high concentrations of NO prevail, such as in endotoxin shock.19 20
| Materials and Methods |
|---|
|
|
|---|
Measurement of Contractility
Arteria Tibialis
The arteria tibialis, a second order branching from
arteria femoralis, was dissected and transferred to the experimental
chamber containing ice-cold physiological buffer. The chamber was
perfused at 37°C and a rate of 2
mL/min.21 A
permanent intravascular pressure of 80 mm Hg was applied at nonflow
conditions, resulting in an inner vessel diameter of 65% to 85% of
the diameter obtained in Ca2+-free solution.
The diameters of fully relaxed wt and
cGKI/ vessels were 78±6 µm (n=6) and
68±5 µm (n=7), respectively. These values are not significantly
different. All compounds were applied to the adventitial side. Final
concentrations are always reported. Diclofenac (1 µmol/L) was present
in all buffers. To block endothelial NOS, 30 µmol/L L-NOARG was added
60 minutes before DEA-NO.
Aorta
Aortic rings from male mice were prepared as
described
elsewhere.17 For
other experimental details, see our previous
study.17
Analysis of BKCa Channel
Activity
Aortic smooth muscle cells were isolated as described
elsewhere.22
Membrane currents were recorded in whole-cell configurations. The bath
solution contained (in mmol/L) NaCl 140, KCl 5.6,
CaCl2 1.8, MgCl2 1,
glucose 10, and HEPES 10 (pH 7.4). The pipette solution contained KCl
40, potassium aspartate 100, NaCl 10, MgATP 3, glucose 10, HEPES 10,
and 300 nmol/L free calcium (pH 7.4). The holding potential was -20
mV. Test pulses lasted 500 ms to potentials from -30 to +80 mV.
Amplitudes of the final 50 ms of depolarizing test pulses were averaged
from 3 to 5 consecutive trials.
Determination of Cyclic Nucleotide
Levels
Aortic rings were incubated for 10 minutes with
norepinephrine (NE) followed by vehicle (100 µmol/L NaOH) or
100 nmol/L or 100 µmol/L DEA-NO for 3 minutes. Aortic rings were
transferred into liquid nitrogen and pulverized together with 400 µL
10% trichloracetic acid (TCA) under liquid nitrogen. After thawing and
centrifugation, the supernatant was extracted 5 times with 5 volumes of
ether. The ether was evaporated at 70°C for 10 minutes. cGMP and cAMP
were determined by specific enzyme immunoassays (Cayman
Chemical).
| Results |
|---|
|
|
|---|
Acetylcholine (1 nmol/L to 1 µmol/L) that stimulates the
endothelial NO synthesis induced a concentration-dependent relaxation
only in small arteries of wt but not
cGKI/ mice
(Figures 1A
and 1B
), suggesting that cGKI is essential for
endothelium-dependent relaxation. Endothelial dysfunction has been
reported in hypertensive animals and
humans.24 To rule
out that the defect in relaxation was caused by a dysfunction of the
endothelium, the NO donor DEA-NO was applied directly to the arteries
(Figure 1C
). NO relaxed the wt vessels
concentration-dependently without affecting the tone of the
cGKI/ vessels up to a concentration of 1
µmol/L. However, high concentrations of DEA-NO (10 µmol/L) relaxed
partially cGKI/ vessels, suggesting
regulation of vascular tone independent of cGKI. The cAMP-dependent
regulation of the small vessel contractility was not disrupted in
cGKI/ mice
(Figure 1D
). Adenosine acting via cAMP/cAK elicited a similar
relaxation in wt and cGKI/ vessels,
confirming that cAMP relaxes arteries independent of
cGKI.17
|
BKCa Channels Are
Involved in Acetylcholine-Induced Relaxation
The above results suggest that high concentrations of
NO relaxed the vessels by mechanisms independent of cGKI. Previously,
it was shown that NO can affect smooth muscle contractility by
hyperpolarizing the membrane potential through direct or indirect
activation of BKCa channels, which are widely
distributed in vascular smooth
muscle.14 We tested
the contribution of BKCa channels to the
cGMP/cGKI-mediated relaxation in small vessels using the specific
BKCa channel blocker IBTX. Relaxation of wt
small arteries induced by 100 nmol/L ACh was significantly reduced by
200 nmol/L IBTX (n=6, P<0.05;
Figure 2A
), indicating that ACh-induced relaxation was at
least in part mediated by BKCa channels in
murine small vessels. However, the inhibitory effect of IBTX was no
longer observed when the concentration of ACh was raised to 1 µmol/L
(Figure 2A
). Similar results were obtained in the presence of
DEA-NO. IBTX partly inhibited vasorelaxation induced by 1 µmol/L
DEA-NO but had no effect on the relaxation induced by 10 µmol/L
DEA-NO
(Figure 2B
). These results confirm that high concentrations
of NO can relax murine arteries independent of
BKCa channels and cGKI.
|
cGKI Is Required to Activate
BKCa Channels
A direct activation of BKCa
channels by NO has been
reported.11 An
electrophysiological analysis of the BKCa
channels in isolated murine smooth muscle cells from small vessels was
not feasible because of the extremely low amount of cells obtained.
Others have used isolated aortic smooth muscle cells to investigate the
regulation of BKCa
channels.11
Therefore, we tested whether the relaxation of murine aortic rings was
also affected by inhibition of BKCa channels
(Figure 2C
). ACh-induced (10 µmol/L) relaxation of aortic
rings was attenuated by 50% in the presence of 200 nmol/L
IBTX.
This finding encouraged us to analyze the regulation of
BKCa channels in isolated aortic wt and
cGKI/ smooth muscle cells
(Figures 3A
and 3B
). In wt cells, BKCa
currents were increased by 250 nmol/L and 5 µmol/L DEA-NO
(Figure 3A
), and the DEA-NOincreased current was inhibited
by 100 nmol/L IBTX. The current increase was significant at a membrane
potential of +20 mV
(Figure 3A
, inset). In contrast, DEA-NO up to a concentration
of 50 µmol/L had no effect on the activity of
BKCa channels in
cGKI/ smooth muscle cells
(Figure 3B
and inset). In agreement with other
reports,25 26 27 28
this finding indicates that NO regulates murine
BKCa channels only in the presence of
cGKI.
|
NO-Dependent Relaxation of Aortic Rings
To gain more insight into the molecular mechanism of
NO-dependent relaxation in cGKI/vessels,
rings from wt and cGKI/ thoracic aorta
were precontracted with NE and then incubated with increasing
concentrations of DEA-NO. DEA-NO relaxed the wt and
cGKI/ aorta with
EC50 values of 35 and 850 nmol/L, respectively
(Figures 4A
and 4B
). These results are in agreement with those
obtained from small arteries and show that NO at higher concentrations
induced vascular relaxation by an unidentified mechanism in small and
large vessels.
|
In the next series of experiments, we investigated whether
the relaxing effect of NO depended on the synthesis of cGMP. WT and
cGKI/ aortic rings were preincubated
with the competitive inhibitor of soluble guanylyl cyclase, ODQ (3
µmol/L). ODQ shifted the dose-response curves in each genotype to
higher concentrations of NO with EC50 values of
3 and 60 µmol/L
(Figures 4A
and 4B
), proving that cGMP synthesis was required
for NO-induced relaxation of cGKI/
aortic rings. Because cAMP/cAK-dependent relaxation was not impaired in
the cGKI/ vessels
(Figure 1D
; see also Figures 2B
and 2C
in reference 17), it
was possible that cGMP relaxed the aortic rings by cross-activation of
the cAMP-signaling pathway. Addition of Rp-8-Br-cAMPS, a competitive
antagonist of cAMP at the cAMP-binding sites of cAK, did not affect the
dose-response curve for DEA-NO in wt aortas. Rp-8-Br-cAMPS inhibited
effectively relaxation of aortic rings by the
adenosine-A2 receptor agonist CGS21680
(Figure 4C
). The A2 receptor has been
shown to relax murine aortic rings through activation of cAK and
independent of
cGKI.17 29
Therefore, these results support the notion that low concentrations of
NO relaxed vascular smooth muscle exclusively via cGKI and not via cAK.
In contrast, preincubation of the cGKI/
aortic rings with Rp-8-Br-cAMPS increased the
EC50 of DEA-NO 10-fold, from 0.85 µmol/L to
9.4 µmol/L
(Figure 4B
). This 10-fold shift supported the hypothesis that
cGMP relaxed cGKI/ aorta by
cross-activation of cAK.
Cyclic Nucleotide Levels in WT and
cGKI/ Aorta
The experiments carried out so far are compatible with
the hypothesis that NO-increased cGMP levels can affect vascular tone
by activation of the cAMP/cAK signaling pathway. However, the above
finding did not determine whether cGMP inhibited the activity of a
cAMP-hydrolyzing phosphodiesterase and thereby increased the cellular
cAMP concentration or activated directly the cAK. Direct activation of
cAK by cGMP requires cGMP concentrations around 10
µmol/L,30 whereas
phosphodiesterase III is inhibited by cGMP with an
IC50 value of 0.13
µmol/L.31 Using
the difference in required cGMP concentration as criterion should allow
differentiation between a direct and indirect activation mechanism by
measuring NO-stimulated cGMP and cAMP levels. The cyclic nucleotide
levels were measured in aortic rings of wt and
cGKI/ mice before and after the addition
of a low (100 nmol/L) and high (100 µmol/L) concentration of DEA-NO
under the same conditions used for the relaxation experiments
(Figure 5
). DEA-NO at a concentration of 100 nmol/L increased
cGMP levels 2-fold in both genotypes but had no significant effect on
the cAMP levels. These cGMP levels activate cGKI in wt
vessels.32 The high
concentration of DEA-NO stimulated cGMP level over 80-fold in both
tissues. cAMP levels were not increased significantly. Assuming a 60%
water content of the aortic rings, the final cGMP concentration of 30
pmol/mg wet weight yields a cytosolic cGMP concentration of 50
µmol/L. This cGMP concentration exceeds 5-fold the
Ka values for activation of
cAK.30 These values
strengthen additionally the conclusion that high concentrations of
DEA-NO relaxed small and large vessels in the absence of cGKI by
cross-activation of cAK.
|
| Discussion |
|---|
|
|
|---|
The molecular mechanisms involved in NO-mediated regulation
of BKCa channels presently are not clear. It was
reported that the activity of these channels is regulated directly by
NO11 by
cGKI-dependent phosphorylation of the channel
protein25 26 27
or of a protein
phosphatase.28 33 34
NO-dependent activation of BKCa channels was
only observed in the presence of cGKI. Even a concentration of 50
µmol/L DEA-NO did not activate BKCa channels
in mice lacking cGKI
(Figure 3
). In agreement with these results, IBTX did not
prevent relaxation induced by high NO concentrations. These findings
establish firmly that NO activates BKCa channels
in murine vascular smooth muscle via cGKI. This implies that
BKCa channels or closely associated proteins are
in vivo targets for cGKI.
ACh induced relaxation in the presence of IBTX. Similar experiments led to the detection of EDHF, a family of endothelial-derived hyperpolarizing factors.18 It is possible that ACh induced relaxation by stimulating the production of EDHF and not by that of NO. However, IBTX-independent relaxation was also observed when NO was applied directly to the vessels. NO has not been reported to stimulate the production of EDHF, suggesting that relaxation in the presence of IBTX was caused through a different pathway involving cGMP. Possible targets of cGKI that regulate vascular tone could be IRAG, a protein modulating calcium release from IP3-sensitive stores,35 and myosin phosphatase.36 Phosphorylation of these proteins could be involved in the IBTX-insensitive relaxation of wt vessels.
Numerous cGMP-independent effects of NO have been described.37 Experiments designed to test alternative pathways suggested that NO effects were mediated by cGMP even in the cGKI/ mice. The inhibition of the soluble guanylyl cyclase by the competitive inhibitor ODQ shifted the dose relaxation curves to higher concentrations of NO. Activation of cAK by cGMP was identified as the most likely pathway leading to relaxation. cGMP-dependent activation of cAK has been observed previously in isolated smooth muscle cells after downregulation of cGKI.10 The mechanism by which cAK relaxes vascular tone is not known. It is unlikely that cAK activated BKCa channels, because relaxation of cGKI/ vessels occurred in the presence of IBTX.
The cGKI/ mice develop hypertension that could be caused by endothelial dysfunction.24 A change in endothelial function associated with a reduced but not abolished vascular responsiveness to ACh as well as vascular remodeling has been proposed as a common phenomenon in hypertension. The wall thickness as potential index of vascular remodeling23 was not altered in cGKI/ small arteries, demonstrating no compensatory effects in the young mutant mice. The data presented here do not exclude an impaired endothelium-dependent relaxation in older cGKI/ mice. The evidence presented in this study and a previous one17 supports the hypothesis that the lack of smooth muscle cGKI caused hypertension. The relaxation induced by DEA-NO or 8-Br-cGMP did not depend on a functional endothelium.17 Hence, it is very likely that the cGKI deficiency and not endothelial dysfunction led to the impaired ACh/NO-dependent vasorelaxation.
There is clear evidence from this and a previous
study17 that the
NO/cGMP and adenosine/cAMP cascades regulate vascular tone in mice
independent of each other under physiological conditions.
cGMP-dependent activation of cAK was responsible for the relaxation
obtained at high concentrations of NO. This pathway is not operative
under physiological conditions, as shown in
Figure 4A
. However, under pathophysiological circumstances,
for example, during endotoxin shock when NO production is high,
activation of cAK by cGMP may be an additional regulatory mechanism
that produces generalized
hypotension.19 20
| Acknowledgments |
|---|
This work was supported by grants from Deutsche Forschungsgemeinschaft, Thyssen-Stiftung (grant 9.26/91), and Fond der Chemie. We thank M. Wöckner, S. Kamm, and A. Salusky for excellent technical assistance.
Received February 23, 2000; revision received August 23, 2000; accepted August 29, 2000.
| References |
|---|
|
|
|---|
2. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman M. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239242.[Medline] [Order article via Infotrieve]
3.
Shesely
EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa
WC, Smithies O. Elevated blood pressure in mice lacking endothelial
nitric oxide synthase. Proc Natl Acad Sci
U S A. 1996;93:1317613181.
4.
John SW,
Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG, Smithies
O. Genetic decrease in atrial natriuretic peptide and salt-sensitive
hypertension. Science. 1995;267:679681.
5. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL, Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378:6568.[Medline] [Order article via Infotrieve]
6.
Oliver
PM, John SW, Prudy KE, Kim R, Maeda N, Goy MF, Smithies O. Natriuretic
peptide receptor 1 expression influences blood pressures of mice in a
dose-dependent manner. Proc Natl Acad Sci
U S A. 1998;95:25472551.
7. Griffith TM, Edwards DH, Davies RL, Harrison TJ, Eans KT. EDRF coordinates the behaviour of vascular resistance vessels. Nature. 1987;329:442445.[Medline] [Order article via Infotrieve]
8. Weisbrod RM, Griswold MC, Yaghoub M, Komalavilas P, Lincoln TM, Cohen RA. Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide. Br J Pharmacol. 1998;125:16951707.[Medline] [Order article via Infotrieve]
9.
Cohen
RA, Weisbrod RM, Gericke M, Yaghoubi M, Bierl C, Bolotina VM. Mechanism
of nitric oxideinduced vasodilatation: refilling of intracellular
stores by sarcoplasmic reticulum Ca2+ ATPase
and inhibition of store-operated Ca2+
influx. Circ Res. 1999;84:210219.
10. Soff GA, Cornwell TL, Cundiff DL, Gately S, Lincoln TM. Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP. J Clin Invest. 1997;100:25802587.[Medline] [Order article via Infotrieve]
11. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen PA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994;368:850853.[Medline] [Order article via Infotrieve]
12. Pfeifer A, Ruth P, Dostmann W, Sausbier M, Klatt P, Hofmann F. Structure and function of cGMP-dependent protein kinases. Rev Physiol Biochem Pharmacol. 1999;135:105149.[Medline] [Order article via Infotrieve]
13. Lincoln TM, Komalavilas P, Boerth NJ, MacMillan-Crow LA, Cornwell TL. cGMP signaling through cAMP- and cGMP-dependent protein kinases. Adv Pharmacol. 1995;34:305322.
14.
Jaggar
JH, Porter VA, Lederer WJ, Nelson MT. Calcium sparks in smooth muscle.
Am J Physiol. 2000;278:C235C256.
15. Hofmann F, Ammendola A, Schlossmann J. Rising behind NO: cGMP-dependent protein kinases. J Cell Sci. 2000;113:16711676.[Abstract]
16. Somlyo AP, Wu X, Walker LA, Somlyo AV. Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Rev Physiol Biochem Pharmacol. 1999;134:201234.[Medline] [Order article via Infotrieve]
17. Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C, Wang G-X, Korth M, Aszodi A, Andersson K-E, Krombach F, Mayerhofer A, Ruth P, Fässler R. Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J. 1998;17:30453051.[Medline] [Order article via Infotrieve]
18. Félétu M, Vanhoutte PM. The alternative: EDHF. J Mol Cell Cardiol. 1999;31:1522.[Medline] [Order article via Infotrieve]
19. Thiemermann C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol. 1990;182:591595.[Medline] [Order article via Infotrieve]
20. Rosenberg RB, Broner CW, ODorisio MS. Modulation of cyclic guanosine monophosphate production during Escherichia coli septic shock. Biochem Med Metab Biol. 1994;51:149155.[Medline] [Order article via Infotrieve]
21.
Schubert
R, Serebryakov VN, Mewes H, Hopp H-H. Iloprost dilates rat small
arteries: role of KATP- and
KCa-channel activation by cAMP-dependent protein
kinase. Am J Physiol. 1997;272:H1147H1156.
22.
Kleppisch
T, Nelson MT. Adenosine activates ATP-sensitive potassium channels in
arterial myocytes via A2 receptors and
cAMP-dependent protein kinase. Proc Natl Acad Sci
U S A. 1995;92:1244112445.
23.
Gibbsons
GH, Dzau VJ. The emerging concept of vascular remodelling.
N Engl J Med. 1994;330:14311438.
24. Boulanger MC. Secondary endothelial dysfunction: hypertension and heart failure. J Mol Cell Cardiol. 1999;31:3949.[Medline] [Order article via Infotrieve]
25.
Robertson
BE, Schubert R, Hescheler J, Nelson MT. cGMP-dependent protein kinase
activates Ca2+-activated
K+ channels in cerebral artery smooth muscle
cells. Am J Physiol. 1993;265:C299C303.
26.
Fukao
M, Mason H, Britton FC, Kenyon JL, Horowitz B, Keef KD. Cyclic
GMP-dependent protein kinase activates cloned
BKCa channels expressed in mammalian cells by
direct phosphorylation at serine 1072. J Biol
Chem. 1999;274:1092710935.
27.
Alioua
A, Tanaka Y, Wallner M, Hofmann F, Ruth P, Meera P, Toro L. The large
conductance, voltage-dependent, and calcium-sensitive
K+ channel, Hslo, is a target of
cGMP-dependent protein kinase phosphorylation in vivo. J
Biol Chem. 1998;273:3295032956.
28.
Zhou
XB, Ruth P, Hofmann F, Korth M. Protein phosphatase 2A is essential for
activation of IK(Ca) by cyclic GMP Kinase in
tracheal smooth muscle and CHO cells. J Biol
Chem. 1996;271:1976019767.
29. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El-Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature. 1997;388:674678.[Medline] [Order article via Infotrieve]
30. Ogreid D, Ekanger R, Suva RH, Miller JP, Sturm P, Corbin JD, Doskeland SO. Activation of protein kinase isozymes by cyclic nucleotide analogs used singly or in combination: principles for optimizing the isozyme specificity of analog combinations. Eur J Biochem. 1985;150:219227.[Medline] [Order article via Infotrieve]
31. Butt E, Beltman J, Becker DE, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA. Characterization of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: topology of the catalytic sites and comparison with other cyclic AMP-binding proteins. Mol Pharmacol. 1995;47:340347.[Abstract]
32.
Jiang
H, Colbran JL, Francis SH, Corbin JD. Direct evidence for
cross-activation of cGMP-dependent protein kinase by cAMP in pig
coronary arteries. J Biol Chem. 1992;267:10151019.
33. White RE, Lee AB, Shcherbatko AD, Lincoln TM, Schonbrunn A, Armstrong DL. Potassium channel stimulation by natriuretic peptides through cGMP-dependent dephosphorylation. Nature. 1993;361:263266.[Medline] [Order article via Infotrieve]
34.
Hall
SK, Armstrong DL. Conditional and unconditional inhibition of
calcium-activated potassium channels by reversible protein
phosphorylation. J Biol Chem. 2000;275:37493754.
35. Schlossmann J, Ammendola A, Ashman K, Zong X, Huber A, Neubauer G, Wang G-X, Allescher HD, Korth M, Wilm M, Hofmann F, Ruth P. Regulation of [Ca2+]i by a signaling complex of IRAG, IP3 receptor and cGMP kinase. Nature. 2000;404:197201.[Medline] [Order article via Infotrieve]
36.
Surks
HK, Mochizuki N, Kasai Y, Georgescu SP, Tang KM, Ito M, Lincoln TM,
Mendelsohn ME. Regulation of myosin phosphatase by a specific
interaction with cGMP-dependent protein kinase I
.
Science. 1999;86:15831587.
37. Fleming I, Busse R. NO: the primary EDRF. J Mol Cell Cardiol. 1999;31:514.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
R. L. Neppl, L. T. Lubomirov, K. Momotani, G. Pfitzer, M. Eto, and A. V. Somlyo Thromboxane A2-induced Bi-directional Regulation of Cerebral Arterial Tone J. Biol. Chem., March 6, 2009; 284(10): 6348 - 6360. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Perkins, D. O. Warner, and K. A. Jones Prolonged treatment of porcine pulmonary artery with nitric oxide decreases cGMP sensitivity and cGMP-dependent protein kinase specific activity Am J Physiol Lung Cell Mol Physiol, January 1, 2009; 296(1): L121 - L129. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Hennenberg, J Trebicka, T Sauerbruch, and J Heller Mechanisms of extrahepatic vasodilation in portal hypertension Gut, September 1, 2008; 57(9): 1300 - 1314. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Dismuke, C. C. Mbadugha, and D. Z. Ellis NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel Am J Physiol Cell Physiol, June 1, 2008; 294(6): C1378 - C1386. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cordaillat, A. Fort, A. Virsolvy, J.-L. Elghozi, S. Richard, and B. Jover Nitric oxide pathway counteracts enhanced contraction to membrane depolarization in aortic rings of rats on high-sodium diet Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1557 - R1562. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Antl, M.-L. von Bruhl, C. Eiglsperger, M. Werner, I. Konrad, T. Kocher, M. Wilm, F. Hofmann, S. Massberg, and J. Schlossmann IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation Blood, January 15, 2007; 109(2): 552 - 559. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Worner, R. Lukowski, F. Hofmann, and J. W. Wegener cGMP signals mainly through cAMP kinase in permeabilized murine aorta Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H237 - H244. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Oelze, A. Warnholtz, J. Faulhaber, P. Wenzel, A. L. Kleschyov, M. Coldewey, U. Hink, O. Pongs, I. Fleming, S. Wassmann, et al. NADPH Oxidase Accounts for Enhanced Superoxide Production and Impaired Endothelium-Dependent Smooth Muscle Relaxation in BK{beta}1-/- Mice Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1753 - 1759. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Muller, L. Cortes-Dericks, L. T. Budnik, B. Brunswig-Spickenheier, M. Pancratius, R. C. Speth, A. K. Mukhopadhyay, and R. Middendorff Homologous and Lysophosphatidic Acid-Induced Desensitization of the Atrial Natriuretic Peptide Receptor, Guanylyl Cyclase-A, in MA-10 Leydig Cells Endocrinology, June 1, 2006; 147(6): 2974 - 2985. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Bornfeldt Nuclear Signaling in Smooth Muscle Cells: Cyclic Nucleotide Phosphodiesterase 1A Moves In Circ. Res., March 31, 2006; 98(6): 720 - 722. [Full Text] [PDF] |
||||
![]() |
F. Hofmann, R. Feil, T. Kleppisch, and J. Schlossmann Function of cGMP-Dependent Protein Kinases as Revealed by Gene Deletion Physiol Rev, January 1, 2006; 86(1): 1 - 23. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Werner, V. Godfrey, R. R. Arnold, G. L. Featherstone, D. Bender, J. Schlossmann, M. Schiemann, F. Hofmann, and K. B. Pryzwansky Neutrophil Dysfunction in Guanosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase I-Deficient Mice J. Immunol., August 1, 2005; 175(3): 1919 - 1929. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sausbier, C. Arntz, I. Bucurenciu, H. Zhao, X.-B. Zhou, U. Sausbier, S. Feil, S. Kamm, K. Essin, C. A. Sailer, et al. Elevated Blood Pressure Linked to Primary Hyperaldosteronism and Impaired Vasodilation in BK Channel-Deficient Mice Circulation, July 5, 2005; 112(1): 60 - 68. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Krieg, S. Philipp, L. Cui, W. R. Dostmann, J. M. Downey, and M. V. Cohen Peptide blockers of PKG inhibit ROS generation by acetylcholine and bradykinin in cardiomyocytes but fail to block protection in the whole heart Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1976 - H1981. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Hofmann The Biology of Cyclic GMP-dependent Protein Kinases J. Biol. Chem., January 7, 2005; 280(1): 1 - 4. [Full Text] [PDF] |
||||
![]() |
J. Yao, N. Hiramatsu, Y. Zhu, T. Morioka, M. Takeda, T. Oite, and M. Kitamura Nitric Oxide-Mediated Regulation of Connexin43 Expression and Gap Junctional Intercellular Communication in Mesangial Cells J. Am. Soc. Nephrol., January 1, 2005; 16(1): 58 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Koeppen, R. Feil, D. Siegl, S. Feil, F. Hofmann, U. Pohl, and C. de Wit cGMP-Dependent Protein Kinase Mediates NO- but not Acetylcholine-Induced Dilations in Resistance Vessels In Vivo Hypertension, December 1, 2004; 44(6): 952 - 955. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. Gonzalez Bosc, M. K. Wilkerson, K. N. Bradley, D. M. Eckman, D. C. Hill-Eubanks, and M. T. Nelson Intraluminal Pressure Is a Stimulus for NFATc3 Nuclear Accumulation: ROLE OF CALCIUM, ENDOTHELIUM-DERIVED NITRIC OXIDE, AND cGMP-DEPENDENT PROTEIN KINASE J. Biol. Chem., March 12, 2004; 279(11): 10702 - 10709. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bonnevier, R. Fassler, A. P. Somlyo, A. V. Somlyo, and A. Arner Modulation of Ca2+ Sensitivity by Cyclic Nucleotides in Smooth Muscle from Protein Kinase G-deficient Mice J. Biol. Chem., February 13, 2004; 279(7): 5146 - 5151. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Feil, S. M. Lohmann, H. de Jonge, U. Walter, and F. Hofmann Cyclic GMP-Dependent Protein Kinases and the Cardiovascular System: Insights From Genetically Modified Mice Circ. Res., November 14, 2003; 93(10): 907 - 916. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Munzel, R. Feil, A. Mulsch, S. M. Lohmann, F. Hofmann, and U. Walter Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase Circulation, November 4, 2003; 108(18): 2172 - 2183. [Full Text] [PDF] |
||||
![]() |
T. Aizawa, H. Wei, J. M. Miano, J.-i. Abe, B. C. Berk, and C. Yan Role of Phosphodiesterase 3 in NO/cGMP-Mediated Antiinflammatory Effects in Vascular Smooth Muscle Cells Circ. Res., September 5, 2003; 93(5): 406 - 413. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L. Jernigan, B. R. Walker, and T. C. Resta Pulmonary PKG-1 is upregulated following chronic hypoxia Am J Physiol Lung Cell Mol Physiol, September 1, 2003; 285(3): L634 - L642. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Rybalkin, C. Yan, K. E. Bornfeldt, and J. A. Beavo Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function Circ. Res., August 22, 2003; 93(4): 280 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gambaryan, E. Butt, K. Marcus, M. Glazova, A. Palmetshofer, G. Guillon, and A. Smolenski cGMP-dependent Protein Kinase Type II Regulates Basal Level of Aldosterone Production by Zona Glomerulosa Cells without Increasing Expression of the Steroidogenic Acute Regulatory Protein Gene J. Biol. Chem., August 8, 2003; 278(32): 29640 - 29648. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Andric, A. E. Gonzalez-Iglesias, F. Van Goor, M. Tomic, and S. S. Stojilkovic Nitric Oxide Inhibits Prolactin Secretion in Pituitary Cells Downstream of Voltage-Gated Calcium Influx Endocrinology, July 1, 2003; 144(7): 2912 - 2921. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Li, J. Ajdic, M. Eigenthaler, and X. Du A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans Blood, June 1, 2003; 101(11): 4423 - 4429. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Wall, S. H. Francis, J. D. Corbin, K. Grimes, R. Richie-Jannetta, J. Kotera, B. A. Macdonald, R. R. Gibson, and J. Trewhella Mechanisms associated with cGMP binding and activation of cGMP-dependent protein kinase PNAS, March 4, 2003; 100(5): 2380 - 2385. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Schmidt, M. Werner, P. A. Heppenstall, M. Henning, M. I. More, S. Kuhbandner, G. R. Lewin, F. Hofmann, R. Feil, and F. G. Rathjen cGMP-mediated signaling via cGKI{alpha} is required for the guidance and connectivity of sensory axons J. Cell Biol., November 7, 2002; 159(3): 489 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Raj and L. Shimoda Oxygen-dependent signaling in pulmonary vascular smooth muscle Am J Physiol Lung Cell Mol Physiol, October 1, 2002; 283(4): L671 - L677. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T Gewaltig and G. Kojda Vasoprotection by nitric oxide: mechanisms and therapeutic potential Cardiovasc Res, August 1, 2002; 55(2): 250 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Feil, N. Gappa, M. Rutz, J. Schlossmann, C. R. Rose, A. Konnerth, S. Brummer, S. Kuhbandner, and F. Hofmann Functional Reconstitution of Vascular Smooth Muscle Cells With cGMP-Dependent Protein Kinase I Isoforms Circ. Res., May 31, 2002; 90(10): 1080 - 1086. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. Tanko and K. Matrougui Can We Apply Results From Large to Small Arteries? Circ. Res., March 22, 2002; 90 (5): e68 - e68. [Full Text] [PDF] |
||||
![]() |
K. D. Keef, J. R. Hume, and J. Zhong Regulation of cardiac and smooth muscle Ca2+ channels (CaV1.2a,b) by protein kinases Am J Physiol Cell Physiol, December 1, 2001; 281(6): C1743 - C1756. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Koh, K. Monaghan, G. P. Sergeant, S. Ro, R. L. Walker, K. M. Sanders, and B. Horowitz TREK-1 Regulation by Nitric Oxide and cGMP-dependent Protein Kinase. AN ESSENTIAL ROLE IN SMOOTH MUSCLE INHIBITORY NEUROTRANSMISSION J. Biol. Chem., November 16, 2001; 276(47): 44338 - 44346. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-B. Zhou, C. Arntz, S. Kamm, K. Motejlek, U. Sausbier, G.-X. Wang, P. Ruth, and M. Korth A Molecular Switch for Specific Stimulation of the BKCa Channel by cGMP and cAMP Kinase J. Biol. Chem., November 9, 2001; 276(46): 43239 - 43245. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bader, E. Butt, A. Palmetshofer, U. Walter, T. Jarchau, and P. Drueckesl A cGMP-Dependent Protein Kinase Assay for High Throughput Screening Based on Time-Resolved Fluorescence Resonance Energy Transfer J Biomol Screen, August 1, 2001; 6(4): 255 - 264. [Abstract] [PDF] |
||||
![]() |
R. D. Swayze and A. P. Braun A Catalytically Inactive Mutant of Type I cGMP-dependent Protein Kinase Prevents Enhancement of Large Conductance, Calcium-sensitive K+ Channels by Sodium Nitroprusside and cGMP J. Biol. Chem., June 1, 2001; 276(23): 19729 - 19737. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L. Jernigan and T. C. Resta Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation Am J Physiol Lung Cell Mol Physiol, June 1, 2002; 282(6): L1366 - L1375. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |